Early sugary diet could mean memory trouble later
New research shows how drinking sugary beverages early in life may lead to impaired memory in adulthood. The study, published today in Translational Psychiatry, also is the first to… read more.
New research shows how drinking sugary beverages early in life may lead to impaired memory in adulthood. The study, published today in Translational Psychiatry, also is the first to… read more.
Karyopharm Therapeutics Inc. announced that the European Commission (EC) has granted conditional marketing authorization for Nexpovio (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine,… read more.
Infants born by cesarean section have a relatively meager array of bacteria in the gut. But by the age of three to five years they are broadly in… read more.
Health Canada issued a Notice of Compliance for Taltz (ixekizumab), from Eli Lilly, injection, 80 mg/mL, for the treatment of pediatric patients from six to less than 18… read more.
The information comes from the diets and health outcomes of 134,297 people from 21 countries spanning five continents, who were tracked by researchers for data on meat consumption… read more.
Celltrion Group announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for the company’s anti-COVID-19 monoclonal antibody… read more.
ASHP (American Society of Health-System Pharmacists) today announced the publication of two landmark reports that articulate a futuristic vision for pharmacy practice, including expanded roles for the pharmacy enterprise… read more.
Merck announced that the European Commission (EC) has approved an expanded label for Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult and pediatric patients aged… read more.
In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass,… read more.
Vertex Pharmaceuticals Incorporated announced that the Australian Therapeutic Goods Administration (TGA) has approved the use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for people with cystic fibrosis (CF) ages 12… read more.
A new once-weekly basal insulin injection demonstrated similar efficacy and safety and a lower rate of low blood sugar episodes compared with a daily basal insulin, according to… read more.
Pacira BioSciences, Inc. announced the FDA has approved the submission of its supplemental new drug application (sNDA) seeking expansion of the Exparel label to include use in patients… read more.